静脉阿维普地尔与瑞德西韦治疗美国COVID-19相关低氧性呼吸衰竭(TESICO):一项随机安慰剂对照试验
TESICO是在美国28个中心开展的随机、安慰剂对照试验,纳入确诊SARS-CoV-2感染、呼吸衰竭起病4天内的住院成人急性低氧性呼吸衰竭患者,采用2×2析因设计或单药随机比较静脉阿维普地尔和瑞德西韦与安慰剂。阿维普地尔组461例改良意向治疗人群中,第90天主要终点(六分类序贯结局)的OR为1.11(95%CI 0.80-1.55;p=0.54),第90天累计死亡阿维普地尔组38% vs 安慰剂组36%(HR 1.04,95%CI 0.77-1.41;p=0.78)。主要安全性终点(第5天死亡、严重不良事件、器官衰竭、严重感染或3-4级不良事件)阿维普地尔组146/231(63%)vs 安慰剂组129/230(56%)(OR 1.40,95%CI 0.94-2.08;p=0.10)。瑞德西韦比较因入组缓慢提前终止,样本量小于计划,无法就安全性和有效性得出确定性结论。
要点
- 阿维普地尔组与安慰剂组第90天六分类序贯结局的OR为1.11(95%CI 0.80-1.55;p=0.54),未显著改善临床结局。
- 第90天累计死亡阿维普地尔组38% vs 安慰剂组36%(HR 1.04,95%CI 0.77-1.41;p=0.78)。
- 第5天主要安全性终点(死亡、严重不良事件、器官衰竭、严重感染或3-4级不良事件)阿维普地尔组146/231(63%)vs 安慰剂组129/230(56%)(OR 1.40,95%CI 0.94-2.08;p=0.10)。
- 瑞德西韦比较仅87例随机、85例纳入改良意向治疗分析,样本量小于计划,无法就安全性和有效性得出确定性结论。
- 数据与安全监察委员会于2022年5月25日因无效建议停止阿维普地尔试验,申办方于2022年6月9日因入组缓慢停止瑞德西韦试验。
适用人群与场景
- 确诊SARS-CoV-2感染、呼吸衰竭起病4天内的住院成人急性低氧性呼吸衰竭患者。
- 基线时431/461(94%)在ICU;271/461(59%)接受经鼻高流量氧疗或无创通气,185/461(40%)接受有创机械通气,5/461(1%)接受ECMO。
- 分层2-4:因随机前已启动瑞德西韦仅随机至阿维普地尔、因瑞德西韦禁忌仅随机至阿维普地尔、因阿维普地尔禁忌仅随机至瑞德西韦。
处置流程与药物剂量
- 阿维普地尔:每日12小时输注,共3天,目标剂量第1天600 pmol/kg、第2天1200 pmol/kg、第3天1800 pmol/kg,静脉给药。
- 瑞德西韦:200 mg负荷剂量,随后100 mg每日维持剂量,总疗程最多10天。
- 安慰剂:对应活性药匹配的生理盐水安慰剂,等体积给药。
研究设计与关键结果
- TESICO为在美国28个中心开展的随机、安慰剂对照试验,采用2×2析因设计或单药随机;2021年4月21日至2022年5月24日共纳入473例参与者。
- 阿维普地尔比较:471例随机至阿维普地尔或匹配安慰剂,改良意向治疗人群461例(阿维普地尔231例、安慰剂230例);中位年龄57岁(IQR 46-66),女性178/461(39%),Black、Hispanic、Asian或其他246/461(53%),White 215/461(47%)。
- 阿维普地尔组与安慰剂组第90天主要终点(六分类序贯结局)OR为1.11(95%CI 0.80-1.55;p=0.54),模型按基线疾病严重程度分层。
- 第90天累计死亡:阿维普地尔组86例死亡、累计38%,安慰剂组83例死亡、累计36%(HR 1.04,95%CI 0.77-1.41;p=0.78)。
- 第5天主要安全性终点(死亡、严重不良事件、器官衰竭、严重感染或3-4级不良事件):阿维普地尔组146/231(63%)vs 安慰剂组129/230(56%)(OR 1.40,95%CI 0.94-2.08;p=0.10)。
- 瑞德西韦比较:87例随机至瑞德西韦或匹配安慰剂(瑞德西韦44例、安慰剂43例),均接受部分输注,85例纳入两药改良意向治疗分析(即2×2析因入组者)。
证据类型、等级与局限
- 证据类型:随机、安慰剂对照试验(TESICO),注册号ClinicalTrials.gov NCT04843761。
- 原文指出瑞德西韦比较样本量小于计划,无法就安全性和有效性得出确定性结论。
对床旁实践的改变
- 作者结论:在COVID-19相关急性低氧性呼吸衰竭患者中,与安慰剂相比,阿维普地尔至第90天未显著改善临床结局。
- 瑞德西韦比较因样本量小于计划,无法就安全性和有效性得出确定性结论。
指南或共识出处
- TESICO试验(NCT04843761),由美国国立卫生研究院(National Institutes of Health)资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure.
METHODS: TESICO was a randomised trial of aviptadil and remdesivir versus placebo at 28 sites in the USA. Hospitalised adult patients were eligible for the study if they had acute hypoxaemic respiratory failure due to confirmed SARS-CoV-2 infection and were within 4 days of the onset of respiratory failure. Participants could be randomly assigned to both study treatments in a 2 × 2 factorial design or to just one of the agents. Participants were randomly assigned with a web-based application. For each site, randomisation was stratified by disease severity (high-flow nasal oxygen or non-invasive ventilation vs invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO]), and four strata were defined by remdesivir and aviptadil eligibility, as follows: (1) eligible for randomisation to aviptadil and remdesivir in the 2 × 2 factorial design; participants were equally randomly assigned (1:1:1:1) to intravenous aviptadil plus remdesivir, aviptadil plus remdesivir matched placebo, aviptadil matched placebo plus remdesvir, or aviptadil placebo plus remdesivir placebo; (2) eligible for randomisation to aviptadil only because remdesivir was started before randomisation; (3) eligible for randomisation to aviptadil only because remdesivir was contraindicated; and (4) eligible for randomisation to remdesivir only because aviptadil was contraindicated. For participants in strata 2-4, randomisation was 1:1 to the active agent or matched placebo. Aviptadil was administered as a daily 12-h infusion for 3 days, targeting 600 pmol/kg on infusion day 1, 1200 pmol/kg on day 2, and 1800 pmol/kg on day 3. Remdesivir was administered as a 200 mg loading dose, followed by 100 mg daily maintenance doses for up to a 10-day total course. For participants assigned to placebo for either agent, matched saline placebo was administered in identical volumes. For both treatment comparisons, the primary outcome, assessed at day 90, was a six-category ordinal outcome: (1) at home (defined as the type of residence before hospitalisation) and off oxygen (recovered) for at least 77 days, (2) at home and off oxygen for 49-76 days, (3) at home and off oxygen for 1-48 days, (4) not hospitalised but either on supplemental oxygen or not at home, (5) hospitalised or in hospice care, or (6) dead. Mortality up to day 90 was a key secondary outcome. The independent data and safety monitoring board recommended stopping the aviptadil trial on May 25, 2022, for futility. On June 9, 2022, the sponsor stopped the trial of remdesivir due to slow enrolment. The trial is registered with ClinicalTrials.gov, NCT04843761.
FINDINGS: Between April 21, 2021, and May 24, 2022, we enrolled 473 participants in the study. For the aviptadil comparison, 471 participants were randomly assigned to aviptadil or matched placebo. The modified intention-to-treat population comprised 461 participants who received at least a partial infusion of aviptadil (231 participants) or aviptadil matched placebo (230 participants). For the remdesivir comparison, 87 participants were randomly assigned to remdesivir or matched placebo and all received some infusion of remdesivir (44 participants) or remdesivir matched placebo (43 participants). 85 participants were included in the modified intention-to-treat analyses for both agents (ie, those enrolled in the 2 x 2 factorial). For the aviptadil versus placebo comparison, the median age was 57 years (IQR 46-66), 178 (39%) of 461 participants were female, and 246 (53%) were Black, Hispanic, Asian or other (vs 215 [47%] White participants). 431 (94%) of 461 participants were in an intensive care unit at baseline, with 271 (59%) receiving high-flow nasal oxygen or non-invasive ventiliation, 185 (40%) receiving invasive mechanical ventilation, and five (1%) receiving ECMO. The odds ratio (OR) for being in a better category of the primary efficacy endpoint for aviptadil versus placebo at day 90, from a model stratified by baseline disease severity, was 1·11 (95% CI 0·80-1·55; p=0·54). Up to day 90, 86 participants in the aviptadil group and 83 in the placebo group died. The cumulative percentage who died up to day 90 was 38% in the aviptadil group and 36% in the placebo group (hazard ratio 1·04, 95% CI 0·77-1·41; p=0·78). The primary safety outcome of death, serious adverse events, organ failure, serious infection, or grade 3 or 4 adverse events up to day 5 occurred in 146 (63%) of 231 patients in the aviptadil group compared with 129 (56%) of 230 participants in the placebo group (OR 1·40, 95% CI 0·94-2·08; p=0·10).
INTERPRETATION: Among patients with COVID-19-associated acute hypoxaemic respiratory failure, aviptadil did not significantly improve clinical outcomes up to day 90 when compared with placebo. The smaller than planned sample size for the remdesivir trial did not permit definitive conclusions regarding safety or efficacy.
FUNDING: National Institutes of Health.
参考来源
- Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023. PMID: 37348524. doi:10.1016/S2213-2600(23)00147-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。